We build cell therapies faster than biology
Generative Biology will revolutionize the development of living therapies
But a bottleneck exists in the effective translation of potential therapeutic proteins from in silico design into the atomic world of medicine. Our Bits to Therapies™ platform solves this bottleneck by screening libraries of de novo protein designs directly in the context of a therapeutic modality. This enables us to design, build, test, and translate cancer cell therapies faster than biology.
Currently funded by:
Investors:
Y Combinator, AgStartup Engine, FIN Capital,
Southeast Minnesota Capital,
Wefunder, various angel investors
Grants:
NSF SBIR, NIH SBIR, LaunchMN,
Regenerative Medicine Minnesota